# US 2021/0340524 A1 · Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340524 A1
- Document ID: US20210340524A1
- Status: Published application
- Kind: A1
- Application number: 17/188,861
- Filed: 2021-03-01
- Published: 2021-11-04
- Earliest claimed: 2020-05-01
- Assignees: Massachusetts Institute of Technology
- Applicants: Massachusetts Institute of Technology
- Inventors: Darrell J. IRVINE; Karl Dane WITTRUP; Naveen MEHTA; Leyuan MA; Benjamin COSSETTE
- Web page: https://patentgrep.com/patent/US20210340524A1

## CPC

- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- A61K 39/001112: {CD19 or B4}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C40B 40/08: Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/6018: {Lipids, e.g. in lipopeptides}
- A61K 2039/6093: {Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine}
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

The disclosure features chimeric antigen receptor (CAR) ligands, methods for making the same, and immunomodulatory compositions comprising the CAR ligands. The disclosure also features compositions and methods of using the immunomodulatory compositions, for example, to stimulate activation of CAR expressing cells.

## Claims

### Claim 1

A method for identifying a peptide ligand that selectively binds a chimeric antigen receptor (CAR), wherein the method comprises:
(i) providing a cellular library comprising a population of cells that display at least 106 unique variable peptides, wherein the variable peptides are 5 or more amino acid residues in length; and
(ii) selecting a peptide sequence motif that binds the CAR antigen-recognition domain with a binding affinity (KD) of at least 5 μM.

### Claim 2 (depends on 1)

The method of claim 1, wherein providing the cellular library comprises (i) transforming a population of cells with a library of vectors, wherein each vector comprises a synthetic polynucleotide that encodes a variable peptide operably-linked to an adhesion protein, and (ii) maintaining the population of cells under conditions that induce expression of the synthetic polynucleotide in a plurality of transformed cells, wherein the cellular library is a phage display library, a viral display library, a yeast display library, a bacterial display library, a mammalian cell display library, or an insect cell display library.

### Claim 3

(canceled)

### Claim 4 (depends on 2)

The method of claim 2, wherein (i) the synthetic polynucleotide encodes a variable peptide that is at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues in length, and wherein each amino acid residue of the variable peptide is encoded by a degenerate codon; or
(ii) wherein the synthetic polynucleotide sequence encoding the variable peptide is (NNK)w, wherein NNK is (A,T,G,C(A,T,G,C(G,T), and wherein w is 5-20.

### Claim at position 5

5-7. (canceled)

### Claim 8 (depends on 4)

The method of claim 4, wherein the cellular library comprises synthetic polynucleotides encoding at least about 1×106, about 5×106, about 1×107, about 5×107, about 1×108, about 5×108, or about 1×109 unique variable peptide sequences.

### Claim 9 (depends on 4)

The method of claim 4, wherein the variable peptide comprises at least two cysteine residues, and wherein the cysteine residues are capable of forming an intra-peptidyl disulfide bond.

### Claim 10 (depends on 4)

The method of claim 4, wherein the synthetic polynucleotide sequence encoding the variable peptide is:
(i) (NNK)x(TGY)(NNK)y(TGY)(NNK)z (SEQ ID NO: 135), wherein NNK is (A,T,G,C)(A,T,G,C)(G,T); wherein TGY is (T)(G)(T,C); wherein x is 1-7; wherein y is 1-7; and wherein z is 1-7; or
(ii) (CGN)(NNK)q(TGY)(CCN)(TGG)(NNK)r(TGY)(NNK)s, (SEQ ID NO: 136), wherein NNK is (A,T,G,C)(A,T,G,C(G,T): wherein CGN is (C)(G)(A,T,G,C) wherein TGY is (T)(G)(T,C) wherein CCN is (C)(C)(A,T,G,C) wherein TGG is (T)(G)(G); wherein q is 1-3; wherein r is 1-3; and wherein s is 1-4.

### Claim at position 9

11-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the cellular library is a yeast display library, and wherein the adhesion protein is Aga2p.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The method of claim 14, wherein the synthetic polynucleotide comprises the nucleotide sequence set forth in SEQ ID NO: 84 or 86; or wherein the synthetic polynucleotide encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 83 or 85.

### Claim at position 13

17-20. (canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein the selection comprises
(i) a negative selection, wherein the negative selection comprises at least one, two, three, four, or five rounds of depletion of cells that bind to a solid support, wherein the solid support comprises binding sites, wherein a plurality of binding sites are unbound or wherein a plurality of binding sites display an isotype control antibody or fragment thereof, and
(ii) a positive selection, wherein the positive selection comprises at least one, two, three, four, or five rounds of enrichment of cells that bind to a solid support, wherein the solid support comprises binding sites, wherein a plurality of binding sites display an antibody or fragment thereof comprising the CAR antigen-recognition domain.

### Claim at position 15

22-30. (canceled)

### Claim 31 (depends on 1)

The method of claim 1, wherein the selection comprises a positive selection, wherein the positive selection comprises at least one, two, three, or four rounds of selection using a method of single-cell sorting, wherein each round of positive selection comprises labeling the population of cells with a fluorescently tagged antibody or fragment thereof comprising the CAR antigen-recognition domain.

### Claim at position 17

32-34. (canceled)

### Claim 35 (depends on 31)

The method of claim 31, wherein the positive selection comprises
(i) at least one round of selection, wherein the population of cells is labeled with the fluorescent antibody or fragment thereof at a concentration of about 1 μM to about 5 μM;
(ii) at least one round of selection, wherein the population of cells is labeled with the fluorescent antibody or fragment thereof at a concentration of about 100 nM to about 1000 nM;
(iii) at least one round of selection, wherein the population of cells is labeled with the fluorescent antibody or fragment thereof at a concentration of about 10 nM to about 100 nM;
(iv) at least one round of selection, wherein the population of cells is labeled with the fluorescent antibody or fragment thereof at a concentration of about 1 nM to about 10 nM (v) at least one round of selection, wherein the population of cells is labeled with the fluorescent antibody or fragment thereof at a concentration of about 0.1 nM to about 1 nM; or
(vi) any combination of (i)-(v).

### Claim at position 19

36-38. (canceled)

### Claim 39 (depends on 35)

The method of claim 35, wherein the positive selection comprises at least one round of selection comprising: (i) labeling with the fluorescent antibody or fragment thereof at a concentration of at least about 10 nM, 15 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 150 nM, 200 nM, 250 nM, 300 nM, 350 nM, 400 nM, 450 nM, or 500 nM or higher, wherein isolated cells express a variable peptide that binds the CAR antigen recognition domain with a binding affinity (KD) of about 1 nM to about 5 μM;
(ii) labeling with the fluorescent antibody or fragment thereof at a concentration of about 0.5 nM to about 1 nM, about 1 nM to about 5 nM, or about 0.5 nM, about 1 nM, about 2 nM, about 3 nM, about 4 nM, about 5 nM, wherein isolated cells express a variable peptide that binds the CAR antigen recognition domain with a binding affinity (KD) of about 1 nM to about 1000 nM; or
(iii) labeling with the fluorescent antibody or fragment thereof at a concentration of about 0.05 nM to about 0.2 nM, about 0.1 nM to about 0.2 nM, or about 0.05 nM, about 0.06 nM, about 0.07 nM, about 0.08 nM, about 0.09 nM, about 0.1 nM, about 0.15 nM, or about 0.2 nM, wherein isolated cells express a variable peptide that binds the CAR antigen recognition domain with a binding affinity (KD) of about 1 nM to about 500 nM.

### Claim at position 21

40-41. (canceled)

### Claim 42 (depends on 39)

The method of claim 39, wherein isolated cells express a peptide sequence motif that binds the CAR antigen recognition domain, and wherein the peptide sequence motif is identified by sequencing the isolated cells.

### Claim 43 (depends on 1)

The method of claim 1, wherein the CAR antigen-recognition domain binds to a disease-associated antigen or a tumor-associated antigen.

### Claim 44

(canceled)

### Claim 45 (depends on 1)

A CAR ligand comprising a peptide comprising an amino acid sequence comprising a sequence motif that binds a CAR antigen recognition domain, wherein the sequence motif is identified by the method of claim 1.

### Claim at position 26

46-63. (canceled)

### Claim 64 (depends on 1)

A method for identifying a peptide ligand with enhanced binding to a CAR antigen recognition domain, wherein the method comprises:
(i) providing a cellular library comprising a population of cells that display at least 106 unique variable peptides, wherein the variable peptides comprise an amino acid sequence from N-terminus to C-terminus represented by the formula:
[A]x-[M]-[B]z;
wherein A, if present, is any amino acid residue;
wherein M is a sequence motif identified by the method of claim 1;
wherein B, if present, is any amino acid residue;
x and z are each integers from 1-20;
wherein either A is present or B is present, or both A and B are present; and
(ii) selecting a peptide that binds the CAR antigen-recognition domain.

### Claim 65

A method for identifying a peptide ligand with enhanced binding to a CAR antigen recognition domain, wherein the method comprises:
(i) providing a cellular library comprising a population of cells that display at least 106 unique variable peptides, wherein the variable peptides comprise an amino acid sequence from N-terminus to C-terminus represented by the formula:
[A]x-[M]-[B]z;
wherein A, if present, is any amino acid residue;
wherein M is a sequence motif comprising an amino acid sequence represented by the formula: N′-[Xaa]n-Cys-[Xaa]m-Cys-[Xaa]n-C′, wherein the sequence motif is capable of forming an intra-peptidyl disulfide bridge; wherein Xaa is any amino acid residue; n=1-10 amino acid residues; m=1-7 amino acid residues;
wherein B, if present, is any amino acid residue;
x and z are each integers from 1-20;
wherein either A is present or B is present, or both A and B are present; and
(ii) selecting a peptide that binds the CAR antigen-recognition domain.

### Claim at position 29

66-67. (canceled)

### Claim 68 (depends on 64)

The method of claim 64, wherein providing the cellular library comprises (i) transforming a population of cells with a library of vectors, wherein each vector comprises a synthetic polynucleotide that encodes the variable peptide operably-linked to an adhesion protein, and (ii) maintaining the population of cells under conditions that induce expression of the synthetic polynucleotide in a plurality of transformed cells, and wherein the cellular library is a phage display library, a viral display library, a yeast display library, a bacterial display library, a mammalian cell display library, or an insect cell display library.

### Claim 69

(canceled)

### Claim 70 (depends on 64)

The method of claim 64, wherein (i) A is present and x is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, and wherein A is encoded by a degenerate codon; and/or (ii) B is present and z is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, and wherein B is encode by a degenerate codon.

### Claim at position 33

71-83. (canceled)

### Claim 84 (depends on 64)

The method of claim 64, wherein the cellular library is a yeast display library, wherein the adhesion protein is Aga2p, and wherein the synthetic polynucleotide comprises a nucleotide sequence from 5′ to 3′ represented by the formula: [P]-[T]-[L]-[V], wherein P is Aga2p, T is a tag, L is a linker, and V is the variable peptide.

### Claim at position 35

85-87. (canceled)

### Claim 88 (depends on 84)

The method of claim 84, wherein the selection comprises
(i) a negative selection, wherein the negative selection comprises at least one, two, three, four, or five rounds of depletion of cells that bind to a solid support, wherein the solid support comprises binding sites, wherein a plurality of binding sites are unbound or wherein a plurality of binding sites display an isotype control antibody or fragment thereof, and
(ii) a positive selection, wherein the positive selection comprises at least one, two, three, four, or five rounds of enrichment of cells that bind to a solid support, wherein the solid support comprises binding sites, wherein a plurality of binding sites display an antibody or fragment thereof comprising the CAR antigen-recognition domain.

### Claim at position 37

89-92. (canceled)

### Claim 93 (depends on 84)

The method of claim 84, wherein the selection comprises a positive selection, wherein the positive selection comprises at least one, two, three, or four rounds of selection using a method of single-cell sorting.

### Claim 94

(canceled)

### Claim 95 (depends on 93)

The method of claim 93, wherein the round of selection comprises:
(i) labeling the population of cells with a fluorescently tagged antibody or fragment thereof comprising the CAR antigen-recognition domain at a concentration;
(ii) washing the population of cells;
(iii) labeling the population of cells with a untagged antibody or fragment thereof comprising the CAR antigen-recognition domain, wherein the labeling of (i) is performed with a concentration of the fluorescently tagged antibody or fragment thereof that is at least 10-100% of the binding affinity (KD) of the sequence motif for the CAR antigen recognition domain, and wherein the labeling of (iii) is performed with a concentration of the untagged antibody or fragment thereof that is at least 10-100 fold higher than the concentration of the fluorescently tagged antibody or fragment thereof.

### Claim at position 41

96-104. (canceled)

### Claim 105 (depends on 88)

The method of claim 88, wherein isolated cells express a peptide that binds the CAR antigen recognition domain, and wherein the peptide is identified by sequencing the isolated cells.

### Claim 106 (depends on 64)

A CAR ligand comprising a peptide comprising a sequence motif that binds a CAR antigen recognition domain, wherein the peptide is identified by the method of claim 64.

### Claim 107 (depends on 106)

The CAR ligand of claim 106, wherein the peptide binds to the CAR antigen recognition domain with (i) a binding affinity (KD) that is increased relative to the sequence motif by about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2-fold; (ii) a substantially reduced dissociation rate relative to the sequence motif; or (iii) a combination of (i)-(ii).

### Claim 108

(canceled)

### Claim 109 (depends on 45)

An immunomodulatory composition comprising the CAR ligand of claim 45, wherein binding of the CAR ligand to the CAR antigen recognition domain activates a T cell expressing a CAR comprising the CAR antigen recognition domain.

### Claim at position 47

110-112. (canceled)

### Claim 113 (depends on 45)

An amphiphilic ligand conjugate comprising (i) the CAR ligand of claim 45 or a multimer thereof; and (ii) a lipid operably linked to the CAR ligand or the multimer, wherein binding of the CAR ligand to the CAR antigen recognition domain activates a T cell expressing a CAR comprising the CAR antigen recognition domain.

### Claim at position 49

114-139. (canceled)

### Claim 140 (depends on 113)

A pharmaceutical composition comprising the amphiphilic ligand conjugate of claim 113, and a pharmaceutically acceptable carrier.

### Claim 141 (depends on 113)

An immunogenic composition comprising the amphiphilic ligand conjugate of claim 113, and an adjuvant.

### Claim at position 52

142-150. (canceled)

### Claim 151 (depends on 45)

A method of activating CAR expressing cells or increasing proliferation of CAR expressing cells in a subject, comprising administering the CAR ligand of claim 45.

### Claim 152 (depends on 45)

A method of stimulating an immune response to a target cell population or a target tissue expressing an antigen in a subject, the method comprising administering to the subject CAR expressing cells specific for the antigen and the CAR ligand of claim 45.

### Claim at position 55

153-158. (canceled)

### Claim 159 (depends on 45)

A method of inducing an anti-tumor response in a subject with cancer, comprising administering to the subject the CAR ligand of claim 45 wherein the subject is receiving or has received CAR expressing cells.

### Claim at position 57

160-164. (canceled)
